Get the Stockscreener App
0.00
100.00%
-0.1325
Nkgen Biotech Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
See More
Previous Close:
$0.1325
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-75.69%
1Y Performance:
-92.59%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.1325
52-Week Range:
$0.00
$0.345
Nkgen Biotech Inc Stock (NKGN) Company Profile
Compare NKGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.00 | 0 | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 99.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 62.21B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Nkgen Biotech Inc Stock (NKGN) Latest News
Alzheimer's Disease Pipeline 2025: Detailed Clinical Trials And FDA-Approved Therapies Review By Delveinsight Neurodon, Sangamo Therapeutics, Nkgen Biotech, Asceneuron, Truebinding, Alector - MenaFN
NKGen Biotech, Inc. (NYSE:NKGN) Short Interest Update - Defense World
NKGen Biotech To Present on Allogeneic Enhanced NK Cells - GlobeNewswire
Breakthrough: NKGen's NK Cell Cancer Therapy Eliminates Need for Harsh Pre-Treatment in Solid Tumors - Stock Titan
Critical Contrast: NKGen Biotech (NYSE:NKGN) & Cortexyme (NASDAQ:CRTX) - Defense World
NKGen Biotech Presents Troculeucel Mechanism of Action with - GlobeNewswire
Revolutionary NK Cell Therapy Transforms Moderate Alzheimer's to Mild Stage in Clinical Trial - Stock Titan
NKGen Biotech to Present at the Alzheimer’s Association International Conference 2025 - GlobeNewswire
Revolutionary NK Cell Therapy Shows Promise in Alzheimer's Disease: Phase 1 Data Reveal Key Insights - Stock Titan
NKGen Biotech Gets FDA Expanded Access - Orange County Business Journal
NKGen Secures FDA Expanded Access For NK Cell Therapy In Neurodegenerative Diseases, Stock Down - Nasdaq
FDA grants expanded access for NKGen’s cell therapy in neurodegenerative diseases By Investing.com - Investing.com South Africa
FDA grants expanded access for NKGen’s cell therapy in neurodegenerative diseases - Investing.com Nigeria
NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases - The Manila Times
NKGen Receives FDA Expanded Access Protocol Authorization - GlobeNewswire
FDA Grants Breakthrough Access: NKGen's NK Cell Therapy Now Available for Multiple Untreatable Brain Diseases - Stock Titan
NKGen Biotech and HekaBio enter strategic partnership to bring novel NK cell therapy to Japan - BioSpectrum Asia
NKGen and HekaBio partner to advance NK cell therapy in Japan - Investing.com India
NKGen Biotech Partners with HekaBio for SNK01 in Japan - TipRanks
NKGen and HekaBio partner to advance NK cell therapy in Japan By Investing.com - Investing.com South Africa
NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan - GlobeNewswire
Vivos Therapeutics shares rise 1.81% premarket after NKGen Biotech's new funding announcement. - AInvest
NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards - GlobeNewswire
NKGen Biotech (NYSE:NKGN) versus CEL-SCI (NYSE:CVM) Head-To-Head Comparison - Defense World
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Quiver Quantitative
Delisting of Securities from The Nasdaq Stock Market - Yahoo Finance
NKGen Biotech (NYSE:NKGN) Stock Price Down 0.2% – What’s Next? - Defense World
NKGen administers first dose of NK cell therapy to Alzheimer’s patient - Investing.com Australia
NKGen administers first dose of NK cell therapy to Alzheimer’s patient By Investing.com - Investing.com South Africa
NKGen Biotech Administers First Dose of Troculeucel to - GlobeNewswire
Breakthrough: New NK Cell Treatment Offers Hope for Alzheimer's Patients Who Failed Standard Therapy - Stock Titan
NKGen activates new sites for Phase I/IIa study of Alzheimer’s cell therapy - yahoo.com
Revolutionary NK Cell Therapy for Alzheimer's Expands Clinical Trial to International Sites - Stock Titan
NKGen Biotech Approved as Preferred Bidder for NKMAX - TipRanks
NKGN gets stakeholder nod for NKMAX takeover; closing slated Aug 2025 | NKGNW SEC FilingForm 8-K - Stock Titan
NKMAX completes sale to NKGen, eyes delisting prevention and future recoveryCHOSUNBIZ - Chosunbiz
Nkgen biotech sees $2.5 million stock purchase by major shareholder - Investing.com Canada
NKGen Biotech Enters Stock Purchase Agreement - TipRanks
NKGen Biotech Delays Quarterly Report Filing - TipRanks
NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally - GlobeNewswire
NKGen Biotech’s Strategic Stock Purchase Agreement - TipRanks
NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations - Stock Titan
NKGen Biotech to Present Phase 1 Clinical Data on Troculeucel for Alzheimer's Disease at ASGCT Annual Meeting - Nasdaq
NKGen Biotech to Present Troculeucel Clinical and Biomarker - GlobeNewswire
NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - Stock Titan
Head-To-Head Review: NKGen Biotech (NYSE:NKGN) and Athira Pharma (NASDAQ:ATHA) - Defense World
NKGen Biotech secures amended loan terms with East West Bank By Investing.com - Investing.com India
NKGen Biotech secures amended loan terms with East West Bank - Investing.com
Nkgen Biotech Inc Stock (NKGN) Financials Data
There is no financial data for Nkgen Biotech Inc (NKGN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.96%
1.09%
Cap:
|
Volume (24h):